Artificial Light at Night and Metabolic Risk: What We Know

Artificial light at night may add to metabolic and mental-health burden long after a diagnosis appears. In people with diabetes, higher outdoor nighttime light correlated with worse measures of glucose control and cardiovascular health. In four national aging cohorts, higher residential outdoor light at night also predicted more depression. These findings do not show that streetlights cause diabetes or depression, but they make a practical point: darkness during sleep belongs on the list of modifiable exposures, especially for people already managing cardiometabolic disease.

The evidence is strongest for an association, not a treatment effect. No randomized trial has shown that blackout curtains, sleep masks, screen curfews, or municipal lighting changes improve fasting glucose, lipids, body weight, or depression in free-living adults. Still, the signal has appeared across indoor light meters, wearable monitors, and satellite estimates in several countries.

Outdoor light tracks with incident obesity in Barcelona

The best prospective study in this group comes from Barcelona. In the 2025 GCAT cohort study, researchers followed 9,752 adults ages 40 to 65 and estimated outdoor artificial light at night using International Space Station imagery. Each interquartile-range increase in photopic outdoor illuminance was associated with a 29% higher hazard of incident obesity (hazard ratio 1.29). The investigators adjusted for nitrogen dioxide, ambient noise, and green-space exposure, reducing—but not eliminating—the chance that nighttime lighting simply tagged other urban exposures.

This result deserves more weight than a typical cross-sectional correlation because it examined new obesity over time and controlled for unusually relevant co-exposures. It still measured residential outdoor light rather than light reaching a participant's eyes. Satellite radiance and a bedroom lux meter do not measure the same thing, so their values cannot be converted into a shared "safe" threshold.

Across observational studies, the average association is modest. A 2022 review summarized meta-analytic estimates of an odds ratio of about 1.13 for overweight and 1.22 for obesity. Those numbers matter at a population level, but they do not put nighttime light in the same league as diet, physical activity, medication effects, or socioeconomic conditions. Think of it as a possible amplifier, not the engine of metabolic disease.

Bedroom light may affect different biomarkers at different hours

Indoor measurements add a more personal, though still incomplete, picture. In Japan, the cross-sectional HEIJO-KYO study measured bedroom light in 2,947 older adults, whose mean age was 69.3 years. At 3 lux or more, participants had more sleep disturbances. At 10 lux or more, they had significantly lower HDL cholesterol and higher white blood cell counts. Those in the highest exposure quartile also had higher BMI, larger abdominal circumference, and higher LDL cholesterol.

The thresholds are useful warning signs, not biological speed limits. Cross-sectional data cannot rule out reverse causation: poorer health, different housing, sleep disruption, and greater nighttime light exposure can travel together. Individual sensitivity also varies. A 2024 meta-analysis of human studies found that nocturnal light suppresses melatonin, with wavelength and timing affecting the magnitude. But population averages cannot tell any one person exactly how much light will disrupt their physiology.

A Chinese cohort study offers an intriguing timing hypothesis. The 2021 study by Xu et al. enrolled 484 young adults and obtained one-year blood follow-up in 230. Light exposure one to four hours after sleep onset was associated with higher fasting insulin and HOMA-IR; for light at four hours after bedtime, the reported coefficients were 0.33 (95% CI, 0.19 to 0.47) for fasting insulin and 0.07 (95% CI, 0.04 to 0.11) for HOMA-IR. Light one hour before waking was associated with higher total cholesterol (β=0.03, 95% CI, 0.02 to 0.04), LDL cholesterol (β=0.02, 95% CI, 0.01 to 0.03), and triglycerides (β=0.015, 95% CI, 0.01 to 0.02).

The split between early-night insulin markers and pre-awakening lipid markers fits circadian biology, but it is not established clinical guidance. The blood-sample follow-up included only 230 people, and no independent study in this evidence base has reproduced the timing pattern. The changes in lipid coefficients were also small; a statistically significant biomarker association is not the same as a meaningful change in cardiovascular events.

People with existing disease may be more exposed to the downside

The disease-modifier question matters because people with diabetes already have less room for additional metabolic stress. In a cross-sectional study of Chinese patients with diabetes, Zhang et al. in 2024 found that higher outdoor artificial light at night correlated with higher HbA1c, fasting glucose, two-hour glucose, and HOMA-IR, and with lower HOMA-B, a marker of beta-cell function. The association between light at night and cardiovascular health was stronger in men, older adults, and urban residents.

That study supports concern, not a causal diagnosis. It cannot determine whether light exposure worsened metabolic control, whether poorer health changed where people lived or how they slept, or whether an unmeasured feature of urban life explained part of the association. Its value lies in showing that the question extends beyond otherwise healthy people.

The neuropsychiatric evidence points in the same direction. A 2025 multicohort study by So et al. examined longitudinal aging surveys in the United States (20,868 participants), England (9,848), Ireland (6,407), and Northern Ireland (2,725). Satellite-derived residential nighttime light was associated with depression across the four cohorts after adjustment for individual- and area-level factors. Depression assessments and follow-up periods differed across surveys, and the exposure estimate had roughly 500-meter resolution, so the study cannot establish personal nighttime light dose or prove causation. Its cross-country replication nonetheless makes the association harder to dismiss as a single-city artifact.

Children and adolescents complicate the dose-response story

Two studies in younger populations reinforce concern while arguing against simplistic thresholds. In 831 Chinese school-aged children wearing personal 24-hour light monitors, each additional 14.4 minutes per day of light at night of at least 1 lux was associated with 3.49% higher body fat (P<0.01). The 2025 wearable-monitor study found a larger association in boys and estimated that reducing nighttime light would have a larger obesity-prevention impact than an equivalent increase in daytime bright light. It was cross-sectional, so this is an association between an exposure pattern and adiposity, not proof that removing light reduces body fat.

In a separate nationally representative sample of 14,804 Chinese youth ages 7 to 17, Ge et al. found a U-shaped association between satellite-derived outdoor light and metabolic syndrome. Above an inflection point of about 15.9 nW/cm²/sr, the odds ratio for metabolic syndrome was 1.104 (95% CI, 1.019 to 1.195); for elevated blood pressure, the corresponding inflection point was about 26.9 nW/cm²/sr and the odds ratio was 1.120 (95% CI, 1.066 to 1.178). The study found no significant nonlinear association for fasting glucose or triglycerides.

The low-light side of that U shape has no settled biological explanation and may reflect residual confounding by urbanization, diet, activity, healthcare access, or other differences between settings. It does not show that some bedroom light is healthy. It does show why a single numerical nighttime-light target would overstate what the field knows.

What human experiments establish—and what they do not

Observational evidence has a plausible physiological basis. A 2022 randomized crossover trial in healthy adults found that controlled nocturnal light exposure altered circadian phase markers and energy-metabolism parameters. The human melatonin meta-analysis supplies a second link: light at night can suppress melatonin, particularly depending on wavelength and timing.

Neither result proves a long-term chain from residential lighting to diabetes, obesity, depression, or cardiovascular events. Acute laboratory exposure differs from years of sleeping in a real home. Proposed effects on pancreatic, liver, adipose, and inflammatory pathways remain a framework for research, not direct proof from these cohorts.

A sensible response: make sleep dark, then keep perspective

If outside or indoor light reaches your bedroom, reducing it is a low-cost experiment with a favorable practical case. Use blackout curtains or a well-fitting sleep mask, cover or move bright electronics, and check for early-morning light leaking around window coverings. People with insulin resistance, diabetes, obesity, or sleep problems have the clearest reason to take the exposure seriously, although no trial yet shows that these changes improve their laboratory results.

Do not treat 3 lux, 10 lux, or any satellite-radiance value as a personal safety guarantee. The studies used different exposure measures, populations, and endpoints. Darkness will not replace treatment for diabetes, depression, obesity, or dyslipidemia. It is a reasonable environmental cleanup while researchers test whether reducing nighttime light changes the outcomes that matter most.

Bottom line: Artificial light at night is consistently associated with poorer cardiometabolic health and, in older adults, depression. The strongest available studies support reducing unnecessary bedroom light; they do not yet prove that doing so reverses disease.